The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...
MedPage Today on MSN3d
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without DiabetesThe number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...
The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Two-Year Persistent Glucagon-Like Peptide-1 Agonist Obesity Without Diabetes Treatment: Clinical Outcomes Among Commercially Insured Among individuals persistent to their GLP-1 therapy over two ...
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback